- This event has passed.
Postponed: Thomas C. Shea BMT and Cellular Therapy Symposium
April 3, 2020 @ 8:30 am - 4:30 pm
Given growing concerns related to COVID-19 and attending public events, we are postponing the symposium. We intend to hold the symposium in spring 2021. Thank you for your understanding.
Come learn about the latest developments in bone marrow transplantation and cellular therapy. The day of talks honors Thomas C. Shea, MD, who recently retired from UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center as the John Pope Distinguished Professor in Cancer Research. Shea is widely respected for his clinical and research contributions that have advanced the bone marrow transplant field.
Shea received his undergraduate and medical degrees from the University of North Carolina at Chapel Hill and completed his residency training in internal medicine and fellowship in hematology and oncology at Beth Israel Hospital in Boston. He undertook additional training in bone marrow transplantation at the Dana-Farber Cancer Institute and was an instructor at Harvard Medical School before starting the bone marrow transplant program at the University of California at San Diego in 1988.
In 1992, he returned to UNC where he established the bone marrow and stem cell transplantation program. He has since had a number of leadership posts at UNC during the past 27 years, including medical co-director of the UNC Bone Marrow Transplant and Cellular Therapy Program and associate director for the UNC Lineberger Clinical Outreach Programs.
In addition to his service to UNC, Shea is lauded for his external leadership roles, including with the Center for International Bone Marrow Transplant Research and the ALLIANCE Transplant and Leukemia Committees. Shea has published extensively in the areas of bone marrow transplantation and the management of patients with hematologic malignancies.
|8:45 a.m.||Opening Comments – Shelley Earp, MD, UNC Lineberger Comprehensive Cancer Center|
|9:00 a.m.||Moving AlloHSCT Forward: The Rationale for PTC – Leo Luznik, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center|
|9:50 a.m.||Improving Immune Reconstitution to Prevent/Treat GI Tract GvHD – Jonathan Serody, MD, UNC Lineberger Comprehensive Cancer Center|
|10:50 a.m.||Targeting B cells To Treat cGvHD – Stefanie Sarantopoulos, MD, PhD, Duke Cancer Institute|
|11:40 a.m.||Targeting Minor Antigens to Enhance the GvL Response – Paul Armistead, MD, PhD, UNC Lineberger Comprehensive Cancer Center|
|1:30 p.m.||CAR T cell Therapy for the Treatment of CNS Disease – Steve Forman, MD, City of Hope|
|2:20 p.m.||Targeting B7-H3 in Solid Tumors – Gianpietro Dotti, MD, UNC Lineberger Comprehensive Cancer Center|
|3:20 p.m.||CD30.CAR T cell Therapy – Natalie Grover, MD, UNC Lineberger Comprehensive Cancer Center|
|4:00 p.m.||Neoantigen Therapy for Cancer – Benjamin Vincent, MD, UNC Lineberger Comprehensive Cancer Center|